following an abbreviated submission
etanercept (Enbrel®) is accepted for restricted use within NHS Scotland.
Indication under review: for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
SMC restriction: use within specialist rheumatology services (including those working within the network for paediatric rheumatology).
Etanercept has previously been accepted for use for this indication in children and adolescents from the age of 4-17 years in NHS Scotland as NHS Health Improvement Scotland advised that NICE Multiple Technology Appraisal No 35 is valid for Scotland.
Etanercept is also listed in the British National Formulary for Children 2011-2012 as one of a number of treatment options for juvenile idiopathic arthritis.
Download detailed advice40KB (PDF)
Medicine details
- Medicine name:
- etanercept (Enbrel)
- SMC ID:
- 782/12
- Indication:
- for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2Â years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Superseded
- Date advice published
- 14 May 2012